TP53 and acute lymphoblastic leukemia: When combined with BBI608, a more pronounced induction of CDKN1A expression was observed, suggesting that the combination treatment enhanced cell cycle arrest and the p53-MDM2 feedback loop in ALL cells (Figure 4A–C).